America Invents Act

America Invents Act
Name	America Invents Act
Enacted by	111th United States Congress
Effective date	March 16, 2013
Public law	Pub. L. 112–29
Signed by	Barack Obama
Introduced in	United States House of Representatives
Related legislation	Leahy–Smith America Invents Act

Contents

America Invents Act The Act was major United States patent law legislation signed into law by Barack Obama during the 111th United States Congress that overhauled aspects of the United States Patent and Trademark Office system and shifted the patent filing regime. It replaced the prior first-to-invent approach with a first-inventor-to-file standard and introduced post-grant review processes, affecting stakeholders including Pharmaceutical Research and Manufacturers of America, Intel Corporation, General Electric, Apple Inc., and Google. The measure had broad implications for litigation in venues such as the United States District Court for the District of Delaware and the United States Court of Appeals for the Federal Circuit and prompted commentary from entities including the American Intellectual Property Law Association, Electronic Frontier Foundation, and Intellectual Property Owners Association.

Background and Legislative History

The legislative push emerged from debates spanning the 109th United States Congress, 110th United States Congress, and the 111th United States Congress with sponsors including Patrick Leahy and Zoe Lofgren and supporters such as John Conyers and Howard Berman. Policy discussions referenced comparative regimes like the European Patent Convention and the Patent Cooperation Treaty while hearings involved witnesses from IBM, Microsoft, Pfizer, and Eli Lilly and Company. Floor action saw negotiations between the United States Senate Committee on the Judiciary and the United States House Committee on the Judiciary and amendments from legislators such as Mel Watt and Darrell Issa. The final bill, often associated with Leahy–Smith, culminated in a signing ceremony at the White House with commentary from the United States Patent and Trademark Office leadership, including David Kappos.

Major statutory shifts included replacing first-to-invent with a first-inventor-to-file regime, establishing inter partes review and post-grant review before the Patent Trial and Appeal Board, modifying prior user rights, and adjusting damages and joinder standards relevant to litigants like Qualcomm and Broadcom. The Act amended provisions of Title 35 of the United States Code, affected practices under the Manual of Patent Examining Procedure, and altered rules surrounding prior art and derivation proceedings. It addressed fee-setting authority related to the America Invents Act's implementation by empowering the United States Patent and Trademark Office to collect certain fees and influenced patentability standards considered in decisions by the Supreme Court of the United States and the United States Court of Appeals for the Federal Circuit.

Implementation required rulemaking by the United States Patent and Trademark Office under directors such as David Kappos and later Michelle Lee, and procedural shifts at the Patent Trial and Appeal Board impacted practitioners from firms like Finnegan, Henderson, Farabow, Garrett & Dunner and Fish & Richardson. Agency guidance referenced international instruments like the Paris Convention for the Protection of Industrial Property and prompted budget discussions involving the United States Department of Commerce and the Congressional Budget Office. Administrative effects included changes to examination timelines, patent backlog metrics reported to the Government Accountability Office, and fee structures scrutinized by the United States Court of Federal Claims.

The new mechanisms such as inter partes review and post-grant review shifted contestation from district courts such as the United States District Court for the Eastern District of Texas to administrative venues like the Patent Trial and Appeal Board, affecting strategies of parties including Samsung Electronics, Sony Corporation, AstraZeneca, and Amgen. Federal appellate review by the United States Court of Appeals for the Federal Circuit and occasional review by the Supreme Court of the United States shaped doctrines on claim construction, estoppel, and invalidity defenses. Litigation trends in jurisdictions like New York and California reflected changes in filing patterns, and multinational firms engaged arbitration and licensing negotiations informed by precedents such as eBay v. MercExchange.

Critics such as the Electronic Frontier Foundation, Pharmaceutical Research and Manufacturers of America, and certain biotechnology firms argued the Act advantaged large corporate filers like Intel Corporation and Microsoft while disadvantaging small inventors and universities like Stanford University and Massachusetts Institute of Technology. Legal challenges targeted procedural aspects at the Patent Trial and Appeal Board and interpretive issues reviewed by the United States Court of Appeals for the Federal Circuit and the Supreme Court of the United States, sparking cases involving parties such as Holmes Group, Inc. and Prometheus Laboratories, Inc.. Academic critique came from scholars affiliated with Harvard Law School, Stanford Law School, and Columbia Law School who analyzed impacts on patent quality and doctrinal shifts.

Empirical studies from institutions including the National Bureau of Economic Research, Brookings Institution, and Harvard Business School evaluated effects on patent quality, patenting rates for entities like IBM and Apple Inc., and innovation incentives in sectors such as pharmaceuticals, semiconductors, and biotechnology. Analyses considered metrics from the United States Census Bureau and the Bureau of Labor Statistics and assessed effects on venture-backed startups in regions like Silicon Valley and Boston. Policymakers in the United States Congress and international observers at the World Intellectual Property Organization continue to debate the Act's influence on patent litigation costs, technology diffusion, and research and development investment by firms such as Pfizer, Merck & Co., Intel Corporation, and Qualcomm.